Member Info for JimiHendrix

Labs are available in theory, but in reality as you know they are not available for the scale and speed of testing that is required.

The deramping gang is out in force lol.

"The huge success of our CYP2C19 product development, offers the NHS an intervention that is estimated to save the NHS £160m every year and improve patient outcomes. This paves the way to a much larger global market than MT-RNR1 with a far less complex route to adoption. The NICE DAP (Diagnostics Assessment Programme) recommendation and the initial first sale demonstrates significant progress."

National Commissioning will bring considerable upside.

A second big 2 million trade showing just now from yesterday, likely a buy too. Seems somebody is building a huge position here.

Lol! ...well more like at least 6 months considering...

• They'll receive payment for the 9 existing NICUs by the end of April.

• First sales to largest Hyper Acute Stroke Centre in NHSE & several other stroke centres expected to implement in advance of NHSE pilot concluding (before April).

• Specialist commissioning for MT-RNR1 on track for April (may not need any more funding after this).

• Scottish NHS rollout for both tests

• Tax credit...

The Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway.

Breakthrough Device Designation received from the U.S. FDA (no competition).

...

Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS.

Receipt of CE-IVD certification (for CYP2C19) in addition to UKCA certification would enable the Company to penetrate markets which it estimates are worth in excess of £100 million per annum. CE-IVD certification expected in the next couple of months (Q1).

…and of course Scottish NHS rollout for both tests.

Also expected before April…

First sales to largest Hyper Acute Stroke Centre in NHSE & several other stroke centres expected to implement in advance of NHSE pilot concluding (so before April).

CYP2C19 CE-IVD by the end of March.

MT-RNR1 - 5 new NICUs for Group B taking part in evidence generation. I think these may be announced before the end of group A’s funding, so before end of April.

Potentially an additional avenue for Genedrive here...

The molecular pathophysiology of hemorrhagic shock represents one of the most complex challenges in critical care medicine, with its devastating impact reflected in mortality rates of 30-40% among trauma patients worldwide and approximately 60,000 deaths annually in the United States alone...

Biomarker implementation faces significant practical obstacles in acute care settings. While numerous molecular markers show prognostic value, current assessment methods often require sophisticated laboratory techniques with processing times incompatible with acute decision-making needs [9,58].

Studies indicate that traditional laboratory-based biomarker assessments fail to capture rapid changes in patient status, potentially missing critical therapeutic windows [142]. Research shows that point-of-care testing, while promising, currently lacks the sensitivity and specificity required for reliable risk stratification and treatment guidance.

Current challenges

Laboratory processing times incompatible with acute care needs; lack of real-time assessment

Impact on patient care

Missed critical therapeutic windows; delayed intervention

Future solutions…

Advanced point-of-care testing development; continuous monitoring systems

Expected benefits

Earlier detection of complications enabling proactive intervention

I wonder if those massive delayed buys are director buys.

Slacker, the share price is not always falling... the general trend since last June is up and there have been rises along the way. The vast majority of growth stocks on AIM spend more than they make, the goal is to make a profitable business over time and they are now on the cusp of this with two world-leading genetic tests for use in near-patient, time critical emergency care settings.

You mentioned you're trying to stop others making the mistake you did when in all likelihood anybody buying now at these prices will probably make a very respectable profit. People who have high averages though and who are not able to average down are in the riskier situation, they need it to multibag and it's them you're affecting most, by attempting to stop any rise.

Interesting, over £100k of delayed buys so far this morning.

At these low share prices I can't understand the constant deramping here. It can only be an attempt to push the price down to allow them to buy at a lower price. If we were up 1000% like some other stocks recently then I'd understand it, but we're rolling along the bottom right now and there are clearly many pieces of positive news expected over the next 2 months that could easily take the price up to 4p for starters (probably a lot higher).

All the below are expected near term... plus a tax credit and a big focus on commercialisation in the Middle East over the next couple of weeks.

1. First sales to largest Hyper Acute Stroke Centre in NHSE & several other stroke centres expected to implement in advance of NHSE pilot concluding (before April)

2. National Commissioning of our products brings significant upside to the sales forecasts (on track for April)

3. Five new NICUs adopting the AIHL test

4. Scottish rollout for both tests (£500k plus?)

5. Another £500k or so from the existing 9 NICUs who will need to fund the tests themselves again after April.

6. CE-IVD for commercial sales within Europe (by April)

They recommended lab testing where available and if it’s practical considering how slow it is. As is clear from many comments from medical professionals and recent articles though lab testing won’t be available at the scale and speed required. So it’ll be the Genedrive POC, which incidentally has recently been proven to outperform lab testing anyway.

I’m expecting a decent push up over the rest of the week and next.

CYP2C19…

Europe & ME: Focus on ME (UKCA) and subsequently Europe with CE-IVD (CE-IVD expected by April).

Middle East & US are key international markets.

Stroke incidence in Middle East is high and age of onset is in younger age group (50% under 45yrs in UAE).

And 4. Payment from the 9 existing NICUs for the test costings after April.

It’s clear that the evidence generation program is maximum 18 months, likely shorter (as per RNS). And the Paloh-UK trial is 24 months. Both began 1st Nov 24.

1. Specialist commissioning is on track for April 2025.

2. Scottish rollout

3. 5 new NICUs to be announced

All of that is regarding AIHL RNR1.

Also just incase anybody is getting confused with these studies, the upto 18 month one is for NICE evidence generation for AIHL (RNR1) but there is also a pilot study going on for the CYP2C19 stroke marker test which will be completed in April.

"First sales to largest Hyper Acute Stroke Centre in NHSE & several other stroke centres expected to implement in advance of NHSE pilot concluding"

Of course as mentioned before, there are plenty of additional positives expected before April too.

Was that you selling? Eureka ...very interesting posting timing and change of tone recently ;)

It's not a problem anyway, anyone can sell anytime for what ever reason they want to. There was a nice 650k buy yesterday or the day before that nobody mentioned. The chart is looking strong at this point again, and in the current market any positive news will probably send this up 100% ...almost daily huge rises recently.